InMode Ltd. (NASDAQ:INMD) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts give InMode a consensus rating of Hold (1 sell, 6 hold, 1 buy) with an average 12‑month price target of $16.00.
• Q1: revenue came in at $82.02M (+5.3% y/y) slightly above estimates, but EPS of $0.25 missed consensus (down from $0.31 a year ago), while net margin remained healthy at ~23.3% and ROE was 13.5%.
• Valuation and sentiment are mixed: market cap ≈ $882M and P/E ~10, the stock is trading near its 52‑week low (50‑day ~$13.8 vs 200‑day ~$14.3), and analyst targets range from a $14 cut (Baird) to a $19 overweight (Barclays), suggesting limited near‑term upside.

InMode Ltd. (NASDAQ:INMD - Get Free Report) has been given a consensus recommendation of "Hold" by the eight brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $16.00.

A number of equities research analysts recently commented on the company. Barclays set a $19.00 price target on InMode and gave the stock an "overweight" rating in a research report on Thursday. Weiss Ratings restated a "sell (d+)" rating on shares of InMode in a research report on Thursday, January 22nd. BTIG Research restated a "neutral" rating on shares of InMode in a research report on Monday, January 26th. Finally, Robert W. Baird decreased their price target on InMode from $17.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday.

InMode Price Performance

NASDAQ INMD opened at $13.92 on Friday. The firm has a market cap of $881.97 million, a PE ratio of 10.24 and a beta of 1.97. InMode has a one year low of $12.72 and a one year high of $16.74. The stock's 50 day simple moving average is $13.81 and its 200 day simple moving average is $14.34.

InMode (NASDAQ:INMD - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The healthcare company reported $0.25 EPS for the quarter, missing analysts' consensus estimates of $0.30 by ($0.05). The business had revenue of $82.02 million for the quarter, compared to the consensus estimate of $79.84 million. InMode had a return on equity of 13.50% and a net margin of 23.27%.The firm's revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $0.31 earnings per share.

Trending Headlines about InMode

Here are the key news stories impacting InMode this week:

• Positive Sentiment: Q1 revenue beat and year-over-year growth: InMode reported GAAP revenue of ~$82.0M, up ~5% y/y and slightly above consensus, and maintained healthy margins and ROE — a constructive signal for the company’s top-line momentum. InMode Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Earnings materials and transcripts available: The company released its press materials, slide deck and the call transcript (useful for details on demand trends, guidance commentary and product mix). Analysts and investors can review the full call transcript for nuance. InMode Ltd. (INMD) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Market context and trading activity: Market-cap ~ $882M, P/E ~9.7, and intraday volume is running above its ~1.0M average — technicals (50-day ~$13.81 vs 200-day ~$14.35) show the stock near the low end of its 52-week range, which can amplify moves on news. (Background data from MarketBeat.)
• Negative Sentiment: EPS miss: Q1 EPS of $0.25 missed the consensus ~$0.29, and EPS declined from $0.31 a year ago — a near-term disappointment that can pressure multiples and sentiment. InMode Q1 Earnings Snapshot / MarketBeat
• Negative Sentiment: Analyst downgrade/price-target cut: Robert W. Baird lowered its price target from $17 to $14 and moved to a "neutral" rating — this reduces upside in short-term analyst guidance and may weigh on sentiment. Baird Lowers InMode Price Target to $14

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Deutsche Bank AG boosted its position in InMode by 35.9% in the 4th quarter. Deutsche Bank AG now owns 3,927 shares of the healthcare company's stock valued at $58,000 after buying an additional 1,037 shares during the last quarter. Quadrant Capital Group LLC boosted its position in InMode by 127.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company's stock valued at $29,000 after buying an additional 1,091 shares during the last quarter. Inspire Investing LLC boosted its position in InMode by 6.1% in the 1st quarter. Inspire Investing LLC now owns 19,366 shares of the healthcare company's stock valued at $265,000 after buying an additional 1,111 shares during the last quarter. Leonteq Securities AG bought a new position in InMode in the 4th quarter valued at $26,000. Finally, Plan A Wealth LLC boosted its position in InMode by 16.2% in the 4th quarter. Plan A Wealth LLC now owns 12,878 shares of the healthcare company's stock valued at $189,000 after buying an additional 1,793 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors.

About InMode

InMode Ltd. NASDAQ: INMD is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode's product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.